U.S. Markets closed

Cabot (CBT) Set to Raise Global Prices of Activated Carbon

Zacks Equity Research
1 / 2

Cabot (CBT) Set to Raise Global Prices of Activated Carbon

Cabot (CBT) decides to raise activated carbon prices in response to escalating raw material costs and currency fluctuations.

Cabot Corporation CBT is set to increase global prices for all activated carbon products. The hike will be put into effect for all shipments made on or after Oct 1, or as contracts permit.

The price hikes will range from 5-10%, depending on the specific activated carbon product and region. The company is raising prices in response to rising raw material costs and currency fluctuations. Cabot is also exposed to higher freight costs as well as environmental compliance control costs at its manufacturing facilities.

Notably, the price increase action will enable the company to support investment in product and application development. Additionally, it will ensure that Cabot will be a long-term and reliable supplier of high-quality activated carbon products and services.
 
In a year’s time, shares of Cabot have outperformed the industry it belongs to. While the stock has gained around 16.8%, the industry saw decline of 1.7%.



Cabot, during its fiscal third-quarter call, said that it expects the Reinforcement Materials segment to continue its strong performance in the fourth quarter on solid operational and commercial execution. For the Performance Chemicals segment, it expects to maintain margins while driving volume growth in specialty Carbons and Formulations.

The Reinforcement Materials segment is benefiting from strong commercial execution that is driving volumes and margin growth. The Performance Chemicals unit is also gaining from the favorable impact of price increase actions. Notably, in the third quarter, sales at both the segments rose year over year.
 
The company is taking appropriate pricing actions to offset feedstock cost inflation. It is also committed toward driving product mix at Performance Chemicals through the launch of products and applications.

Cabot Corporation Price and Consensus

Cabot Corporation Price and Consensus | Cabot Corporation Quote

Zacks Rank & Stocks to Consider

Cabot is a Zacks Rank #3 (Hold) stock.

Some better-ranked companies in the basic materials space are Huntsman Corporation HUN, CF Industries Holdings, Inc. CF and Air Products and Chemicals, Inc. APD.

Huntsman has an expected long-term earnings growth rate of 8.5% and a Zacks Rank #1 (Strong Buy). The company’s shares have gained 4.2% in the past year. You can see the complete list of today’s Zacks #1 Rank stocks here.

CF Industries has an expected long-term earnings growth rate of 6% and a Zacks Rank #2 (Buy). The company’s shares have rallied 54.7% in the past year.

Air Products has an expected long-term earnings growth rate of 16.2% and a Zacks Rank #2. Its shares have risen 11.6% in a year’s time.

The Hottest Tech Mega-Trend of All
 
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
 
See Zacks' 3 Best Stocks to Play This Trend >>

  • What Kind Of Shareholders Own Power Financial Corporation (TSE:PWF)?
    Business
    Simply Wall St.

    What Kind Of Shareholders Own Power Financial Corporation (TSE:PWF)?

    A look at the shareholders of Power Financial Corporation (TSE:PWF) can tell us which group is most powerful. Companies that used to be publicly owned tend to have lower insider ownership. Power Financial has a market capitalization of CA$20b, so it's too big to fly under the radar.

  • Business
    Associated Press

    Wayfair: 4Q Earnings Snapshot

    The average estimate of 13 analysts surveyed by Zacks Investment Research was for a loss of $1.30 per share. The online home goods retailer posted revenue of $2.01 billion in the period, which also beat Street forecasts. Thirteen analysts surveyed by Zacks expected $1.97 billion.

  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of ES earnings conference call or presentation 21-Feb-19 2:00pm GMT

    This equity will help fund the nearly $13 billion of core business and capital investments we expect to make through 2023 and also our 50% of the capital requirements associated with the construction of the Off-Shore Wind facilities for which we and Ørsted have secured PPAs, as Jim talked about earlier. We'll also use treasury shares to satisfy our dividend reinvestment program needs. Our expectation to grow earnings per share around the midpoint of the 5% to 7% range through 2023 anticipates the issuance of this equity over the 5 years.

  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of CSNA3.SA earnings conference call or presentation 21-Feb-19 3:00pm GMT

    We believe that because of the quality of our assets and the possibility of the financial operations that we can carry out in the short term, this outlook of ending the year with a net debt/EBITDA ratio of less than 3 and also with enhancements in our operational results as we believe that 2019 will be better than 2018. Doubtlessly, we will be able to deliver to the market this commitment that we took on last year. As you can see, we look upon the year 2019 with significant optimism.

  • Roche Reportedly Near $5 Billion Takeover Of Gene Therapy Firm Spark
    Business
    Investor's Business Daily

    Roche Reportedly Near $5 Billion Takeover Of Gene Therapy Firm Spark

    Roche is reportedly nearing a deal to acquire gene therapy player Spark Therapeutics for $5 billion as the Swiss drugmaker looks to expand its hemophilia treatments. According to the Wall Street Journal, the deal could be announced Monday, or sooner, and value Spark at $5 billion. The Journal cited people familiar with the matter.

  • Cabot Oil & Gas Corp (COG) Q4 2018 Earnings Conference Call Transcript
    Business
    Motley Fool

    Cabot Oil & Gas Corp (COG) Q4 2018 Earnings Conference Call Transcript

    As some of you may recall this time last year, we laid out a strategy for 2018, that was focused on first delivering growth in production and reserves per debt adjusted share, while generating positive free cash flow. Secondly, generating and improving return on capital employed, that exceeds our cost of capital.

  • Forget Buckeye Partners: Here Are 3 Better Dividend Stocks
    Business
    Motley Fool

    Forget Buckeye Partners: Here Are 3 Better Dividend Stocks

    That's why investors should forget about Buckeye Partners' high-yielding dividend and instead examine the offerings of fellow energy infrastructure companies EnLink Midstream (NYSE: ENLC), Noble Midstream (NYSE: NBLX), and Tallgrass Energy (NYSE: TGE). Each pays a similarly high-yielding dividend that they back with stronger financials metrics and expect to increase at a healthy rate in 2019 and beyond. A higher yield with more growth EnLink Midstream currently offers investors a higher-yielding distribution than Buckeye at 9.7%.

  • Sears Is Getting a New Look
    Business
    Meredith Videos

    Sears Is Getting a New Look

    And, eventually, a new name.

  • Could Medical Marijuana Be a Millionaire Maker Stock?
    Business
    Motley Fool

    Could Medical Marijuana Be a Millionaire Maker Stock?

    To answer the headline question: Sure, Medical Marijuana Inc. (NASDAQOTH: MJNA) could be a millionaire-maker stock -- if one started out as a multimillionaire, perhaps. With that said, let's examine why Medical Marijuana stock isn't likely to pan out as a good investment and discuss some better alternatives -- including Canopy Growth (NYSE: CGC) -- for those who want to invest in the hemp-derived cannabidiol (CBD) space. The U.S. Farm Bill, which became effective on Jan. 1, made it legal across the country to grow and process industrial hemp, opening up a potentially huge market for hemp-derived CBD products.

  • 4 Reasons iQiyi Soared After Its Q4 Earnings Report
    Business
    Motley Fool

    4 Reasons iQiyi Soared After Its Q4 Earnings Report

    The stock ended its first day of trading at $15.50 before soaring as much as 193% by summer, as excitement for the "Netflix of China" grew. Slowing economic growth in China and a trade war with the U.S. took the wind out of iQiyi's sails in late 2018, causing the stock to fall below its IPO price early this year. Better-than-expected results and a strong forecast from iQiyi sent the "IQ" symbol soaring nearly 22% on Friday in the wake of the company's solid fourth-quarter 2018 earnings report.

  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of CATM earnings conference call or presentation 21-Feb-19 10:00pm GMT

    This growth was driven by strong same-store transactions of 6%, led by double-digit growth in surcharge-free transactions from the Allpoint and bank branding products in the U.S. Our transaction driving initiatives with financial institutions and retailers are working. Additionally, we continue to add new partners to Allpoint, enabling 21 new financial institutions to our network in the fourth quarter, bringing with them over 1 million additional cardholders. New Allpoint members include RBC Bank in the U.S.; Qapital, with a Q, an innovative and fast-growing consumer, nontraditional financial services provider; and Visa, enrolling their prepaid and debit cardholders traveling to the U.S. fro...

  • Mark Cuban explains how to make a 16% guaranteed return
    Business
    MarketWatch

    Mark Cuban explains how to make a 16% guaranteed return

    As Mark Cuban, the “Shark Tank” star, billionaire entrepreneur, and NBA franchise owner explains, just pay off your debts. The personal finance site NerdWallet put our revolving credit card balance at $420.22 billion in late 2018. The revolving number is just the credit card debt we carry from month to month.

  • Cisco CEO on 5G technology: Reality is going to match the hype
    Business
    Fox Business Videos

    Cisco CEO on 5G technology: Reality is going to match the hype

    Cisco CEO Chuck Robbins discusses the concerns surrounding Huawei, cyber security and his outlook on 5G technology.

  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of SUN earnings conference call or presentation 21-Feb-19 3:30pm GMT

    And then on the acquisition landscape, can you just give us some color on what you're seeing post -- having done 4 in 2018, but just what you're seeing for this year, maybe 2020, maybe touching on the acquisitions by channel or type of assets? Joseph Kim, Sunoco LP - President, CEO & Director of Sunoco GP LLC [5] Sure.

  • 3 Dividend Stocks That Are Actually Worth Owning
    Business
    InvestorPlace

    3 Dividend Stocks That Are Actually Worth Owning

    You may buy a $50 stock with a 2% dividend, but if that dividend then doubles over the course of several years, and the stock price doubles as well, the effective yield on that $50 investment becomes 4%. Nadella's Microsoft avoids the media spotlight, it talks softly but carries the big technology stick.

  • 'Father of Reaganomics' says 'get out of the market' — bond and stock market — 'and put your money in cash'
    Business
    MarketWatch

    'Father of Reaganomics' says 'get out of the market' — bond and stock market — 'and put your money in cash'

    The Dow Jones Industrial Average (DJIA)is up 19.4% since that time, breaking above a psychologically significant at 26,000 level on Friday, while the S&P 500 index (SPX) has advanced 19.5%, the Nasdaq Composite Index (COMP) has risen 22.4% and the small-capitalization focused Russell 2000 index has returned more than 25%, according to FactSet data. Much of that gain has been underpinned by a Fed that has signaled that it is likely to slow a reduction of its $4 trillion balance sheet as soon as this year and a willingness to wait before increasing borrowing costs further. Both of those plans had been cited as a source of friction for markets.

  • Better Buy: OrganiGram Holdings vs. Aurora Cannabis
    Business
    Motley Fool

    Better Buy: OrganiGram Holdings vs. Aurora Cannabis

    The performance of OrganiGram Holdings (NASDAQOTH: OGRMF) stock trounced that of Aurora Cannabis (NYSE: ACB) in 2018. Does that make OrganiGram the better stock? The reality is that the potential for marijuana stocks -- like stocks in any industry -- depend over the long run on business prospects rather than past gains.

  • Business
    Motley Fool

    The Knockout Restaurant Stock Flying Under the Radar

    The roundup for today's MarketFoolery includes Tesla (NASDAQ: TSLA), Texas Roadhouse (NASDAQ: TXRH), some general investing advice, and an international growth story that deserves more attention. Texas Roadhouse has been quietly knocking it out of the park for years, but the market doesn't seem to care about yet another stellar report this week. The head of Motley Fool Asia David Kretzmann explains why Malaysia is such an exciting opportunity for investors.

  • General Electric's Stock: The Bull vs. The Bear
    Business
    Motley Fool

    General Electric's Stock: The Bull vs. The Bear

    In anticipation of that, it's time to look at how investors -- bulls and bears alike -- should think about the stock. Why the recent earnings concerned the bears The bulls' and bears' debate over GE stock is almost as much about how they value stock as it is about the company's current earnings trajectory. The bears tend to focus on valuing the company in terms of a forward FCF-based valuation; on this basis, the failure to give guidance on industrial FCF is a major concern.

  • Stamps.com Plummets After Nixing Its Exclusive USPS Deal
    Business
    Motley Fool

    Stamps.com Plummets After Nixing Its Exclusive USPS Deal

    Adjusted for items like stock-based compensation and acquisition expenses, (non-GAAP) net income declined 20% year over year to $3.73 per share -- above the $2.90 per share most investors were expecting. Adjusted EBITDA grew 11% to $71.3 million. Paid customers were flat compared to year-ago at 736,000, which is consistent with Stamps.com's strategic focus on acquiring fewer customers with higher lifetime values.

  • Here's Why Karyopharm Therapeutics Is Getting Hammered Today
    Business
    Motley Fool

    Here's Why Karyopharm Therapeutics Is Getting Hammered Today

    Shares of Karyopharm Therapeutics (NASDAQ: KPTI), a precommercial biopharmaceutical company, are plummeting in response to briefing documents released by the Food and Drug Administration ahead of an advisory committee meeting. Karyopharm Therapeutics convinced the FDA to grant a priority review for selinexor, but the agency insisted on an advisory committee meeting to discuss the application with independent experts in a public setting first. During the 123-patient Storm study, 25.4% of patients showed a response to treatment with selinexor plus chemo, which isn't a whole lot better than you'd expect from this group when treated with the same dose of chemo on its own.

  • Dividend ETFs To Buy And Watch For 2019
    Business
    Investor's Business Daily

    Dividend ETFs To Buy And Watch For 2019

    Dividends have long been a favorite of investment gurus from Warren Buffett to late Vanguard Group founder John Bogle, and it's easy to see why. Individual stocks can provide income, but dividend ETFs are an easy way to gain exposure to a basket of dividend-paying stocks. With a stock dividend, a company distributes additional shares instead of cash.

  • Baidu Beats Earnings Expectations, but Still Faces Tough Headwinds
    Business
    Motley Fool

    Baidu Beats Earnings Expectations, but Still Faces Tough Headwinds

    Shares of Baidu (NASDAQ: BIDU) recently rallied after its fourth-quarter earnings topped Wall Street's estimates. The Chinese tech giant's revenue rose 22% annually to 27.2 billion RMB ($3.96 billion), beating expectations by $80 million. Excluding its upcoming divestments, Baidu's revenue went up 28% annually.

  • 20 dividend stocks with 'headroom' to pay investors even more
    Business
    MarketWatch

    20 dividend stocks with 'headroom' to pay investors even more

    The S&P 500 Dividend Aristocrats Index (XX:SPDAUDP) is made up of the 57 companies in the S&P 500 Index (SPX) that have increased their regular dividend payouts for at least 25 consecutive years. The S&P High-Yield Dividend Aristocrats Index is made up of the 112 stocks in the S&P 1500 Composite Index that have raised regular dividends for at least 20 straight years. All Dividend Aristocrats are also High-Yield Dividend Aristocrats.

  • 3 Retail Marijuana Stocks to Watch Now
    Business
    Motley Fool

    3 Retail Marijuana Stocks to Watch Now

    The legal marijuana market in the United States hauled in over $8 billion last year, according to Matt Karnes of GreenWave Advisors. A game-changing acquisition that would significantly increase its retail footprint could close later this year, and if so, MedMen could be in a prime position to become one of the biggest marijuana retailers. MedMen already operates 20 dispensaries in five states, including nine stores in California .